Richard I Steinhart Bio Xcel Therapeutics, Inc. (BTAI) insider trading activity

Richard I Steinhart is Chief Financial Officer of BioXcel Therapeutics, Inc.. Currently has a direct ownership of 6,577 shares of BTAI, which is worth approximately $10,720. The most recent transaction as insider was on Sep 14, 2023, when has been sold 521 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 6.58K

1.04% 3M change

68.58% 12M change

Total Value Held $10,720

Richard I Steinhart Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 14 2023	BUY Exercise of conversion of derivative security	-	521 Added 17.01%	2,542 Common Stock
Jun 14 2023	BUY Exercise of conversion of derivative security	-	521 Added 20.5%	2,021 Common Stock
May 15 2023	SELL Open market or private sale	$135,850 $27.17 p/Share	5,000 Reduced 76.92%	1,500 Common Stock
May 14 2023	BUY Exercise of conversion of derivative security	-	5,000 Added 43.48%	6,500 Common Stock
Mar 15 2023	SELL Open market or private sale	$40,638 $19.5 p/Share	2,084 Reduced 58.15%	1,500 Common Stock
Mar 14 2023	BUY Exercise of conversion of derivative security	-	2,084 Added 36.77%	3,584 Common Stock
Feb 01 2021	SELL Open market or private sale	$180,563 $48.15 p/Share	3,750 Reduced 71.43%	1,500 Common Stock

Feb 01 2021	BUY Exercise of conversion of derivative security	$20,813 $5.55 p/Share	3,750 Added 41.67%	5,250 Common Stock

Also insider at

ATOS

ATOSSA THERAPEUTICS, INC. Healthcare

ATNM

Actinium Pharmaceuticals, Inc. Healthcare

Director

RIS